Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

tasosartan

Known as: 5,8-dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6H)-one, taso-sartan 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Angiotensin II Type 1 Receptor BlockersPyrimidinesTetrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The role of gender relations in decision-making for access to antiretrovirals. A study of the AIDS Support Organisation (TASO) clients, Kampala district, Uganda
The way gender relations influen are and treatment particularly edicines is a challenge to HIV/AIDS programmes and to the… Expand
Review
2001
Review
2001
Pharmacology of AT 1 -receptor Blockers
  • T. Unger
  • Blood pressure. Supplement
  • 2001
    • Corpus ID: 45314205
Angiotensin II mediates its haemodynamic effects by binding to specific cell-surface receptors. In humans, two receptor subtypes… Expand
2000
2000
Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its… Expand
Review
1999
Review
1999
Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics.
  • P. Timmermans
  • Hypertension research : official journal of the…
  • 1999
    • Corpus ID: 9727638
Acceptance of the notion that physiologically specific interruption of the renin-angiotensin-aldosterone system (RAAS) is of… Expand
Review
1999
Review
1999
Pharmacological properties of angiotensin II receptor antagonists.
  • P. Timmermans
  • The Canadian journal of cardiology
  • 1999
    • Corpus ID: 24694991
The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists… Expand
1999
1999
Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study
Abstract Background Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an… Expand
1999
1999
The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
The angiotensin II type 1 (AT(1)) receptor plays a pivotal role in the regulation of blood pressure and electrolyte balance, and… Expand
1998
1998
Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group.
Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist… Expand
1998
1998
Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients
Objective Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal… Expand
1998
1998
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Four Doses of Tasosartan in Patients With Essential Hypertension
Tasosartan, a new, long-act ing, nonpeptide angiotensin II receptor antagonist was evaluated in a randomized, double-blind… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE